Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MIST |
---|---|---|
09:32 ET | 159 | 1.28 |
09:34 ET | 997 | 1.29 |
09:48 ET | 720 | 1.2801 |
09:52 ET | 1100 | 1.2899 |
09:56 ET | 100 | 1.3 |
10:55 ET | 150 | 1.29 |
10:57 ET | 200 | 1.28 |
11:02 ET | 100 | 1.28 |
11:08 ET | 13600 | 1.28 |
11:20 ET | 100 | 1.32 |
11:27 ET | 1262 | 1.32 |
11:29 ET | 100 | 1.3199 |
11:33 ET | 100 | 1.32 |
11:42 ET | 100 | 1.32 |
11:56 ET | 100 | 1.32 |
12:03 ET | 100 | 1.32 |
12:05 ET | 100 | 1.31 |
12:09 ET | 1672 | 1.3 |
12:14 ET | 100 | 1.31 |
12:20 ET | 300 | 1.305 |
12:21 ET | 100 | 1.31 |
12:23 ET | 6148 | 1.32 |
12:32 ET | 1000 | 1.33 |
12:34 ET | 100 | 1.34 |
12:43 ET | 100 | 1.34 |
12:45 ET | 500 | 1.335 |
12:54 ET | 100 | 1.335 |
12:59 ET | 1400 | 1.33 |
01:01 ET | 500 | 1.32 |
01:33 ET | 100 | 1.32 |
01:42 ET | 100 | 1.32 |
01:50 ET | 235 | 1.31 |
01:51 ET | 100 | 1.32 |
02:00 ET | 100 | 1.32 |
02:08 ET | 100 | 1.32 |
02:18 ET | 100 | 1.32 |
02:20 ET | 913 | 1.32 |
02:31 ET | 100 | 1.32 |
02:47 ET | 100 | 1.32 |
02:49 ET | 100 | 1.32 |
02:56 ET | 100 | 1.32 |
03:03 ET | 100 | 1.32 |
03:12 ET | 100 | 1.32 |
03:18 ET | 365 | 1.32 |
03:25 ET | 100 | 1.32 |
03:32 ET | 1100 | 1.31 |
03:34 ET | 131 | 1.31 |
03:38 ET | 459 | 1.3107 |
03:41 ET | 100 | 1.32 |
03:45 ET | 100 | 1.32 |
03:59 ET | 1181 | 1.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Milestone Pharmaceuticals Inc | 71.4M | -1.1x | --- |
MediciNova Inc | 70.1M | -8.4x | --- |
Serina Therapeutics Inc | 73.6M | -0.7x | --- |
Genelux Corp | 73.9M | -2.0x | --- |
Connect Biopharma Holdings Ltd | 73.3M | -1.4x | --- |
Anebulo Pharmaceuticals Inc | 73.4M | -7.5x | --- |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.63 |
EPS | $-1.25 |
Book Value | $0.50 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.